Evidence map›Paper›PMID 38517363›Full record

ArticleAging2024

Omilancor mitigates the senescence of nucleus pulposus cells induced by DDP through targeting MAP2K6.

Fang Yafeng, Shi Xinpeng, Wei Rong, Cui Guofeng

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Fang YafengLuoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
Shi XinpengLuoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
Wei RongLuoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
Cui GuofengLuoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
Luoyang Central Hospital Affiliated to Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study explores the potential of Omilancor in treating Intervertebral Disc Degeneration (IDD) through MAP2K6 targeting.

methodsWe analyzed mRNA microarray datasets to pinpoint MAP2K6 as a key regulator implicated in IDD progression. Follow-up studies demonstrated that cisplatin (DDP) could prompt cellular senescence

resultsWe further showed that administration of Omilancor could significantly alleviate the degeneration of IVDs in annulus fibrosus puncture-induced rat model.

conclusionsOmilancor shows promise as a treatment for IDD by targeting MAP2K6-mediated cellular senescence.

Indexed as

Annulus FibrosusIntervertebral Disc DegenerationNucleus PulposusAnimalsCellular SenescenceMolecular Docking SimulationRatscellular senescenceintervertebral disc degenerationMAP2K6Omilancor

Identifiers

PMID38517363
PMCPMC11006466
OpenAlexW4392975449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.